$VYNE
VYNE Therapeutics Inc. Stock $vyne

$vyne Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000156604421000025 Filed on May 06, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$230.0K	$1.750M
YoY Change	-86.86%	468.18%
Cost Of Revenue	$601.0K	$41.64M
YoY Change	-98.56%	157.16%
Gross Profit	-$371.0K	-$39.89M
YoY Change	-99.07%	151.13%
Gross Profit Margin	-161.3%	-2279.37%
Selling, General & Admin	$5.732M	$25.42M
YoY Change	-77.45%	375.94%
% of Gross Profit
Research & Development	$4.255M	$15.95M
YoY Change	-73.33%	0.19%
% of Gross Profit
Depreciation & Amortization	$27.00K	$93.00K
YoY Change	-70.97%	16.25%
% of Gross Profit
Operating Expenses	$9.987M	$41.37M
YoY Change	-75.86%	110.32%
Operating Profit	-$9.757M	-$39.89M
YoY Change	-75.54%	151.13%
Interest Expense	$1.062M	$1.067M
YoY Change	-0.47%	34.05%
% of Operating Profit
Other Income/Expense, Net	-$57.00K	$723.0K
YoY Change	-107.88%	-9.17%
Pretax Income	-$10.88M	-$40.23M
YoY Change	-72.97%	161.59%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$20.55M	-$40.23M
YoY Change	-48.92%	113.18%
Net Earnings / Revenue	-8934.78%	-2299.03%
Basic Earnings Per Share	-$0.42
Diluted Earnings Per Share	-$0.42	-$3.785M
COMMON SHARES
Basic Shares Outstanding	48.87M shares	24.44M
Diluted Shares Outstanding	48.87M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$119.5M	$57.60M
YoY Change	107.54%	-52.59%
Cash & Equivalents	$118.5M	$57.60M
Short-Term Investments	$1.027M	$0.00
Other Short-Term Assets	$5.800M	$29.30M
YoY Change	-80.2%	691.89%
Inventory	$8.092M	$3.200M
Prepaid Expenses
Receivables	$10.76M	$8.300M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$143.1M	$98.40M
YoY Change	45.44%	-21.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$529.0K	$4.600M
YoY Change	-88.5%	3116.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.100M	$53.50M
YoY Change	-92.34%	26650.0%
Total Long-Term Assets	$6.054M	$62.10M
YoY Change	-90.25%	5660.67%
TOTAL ASSETS
Total Short-Term Assets	$143.1M	$98.40M
Total Long-Term Assets	$6.054M	$62.10M
Total Assets	$149.2M	$160.5M
YoY Change	-7.06%	27.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.500M	$14.10M
YoY Change	-75.18%	271.05%
Accrued Expenses	$13.52M	$13.50M
YoY Change	0.16%	110.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.55M	$56.60M
YoY Change	-61.93%	433.96%
LONG-TERM LIABILITIES
Long-Term Debt	$33.27M	$32.80M
YoY Change	1.45%
Other Long-Term Liabilities	$1.400M	$1.600M
YoY Change	-12.5%
Total Long-Term Liabilities	$33.27M	$34.40M
YoY Change	-3.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.55M	$56.60M
Total Long-Term Liabilities	$33.27M	$34.40M
Total Liabilities	$56.27M	$91.00M
YoY Change	-38.16%	756.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$586.7M
YoY Change
Common Stock	$5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$92.90M	$69.54M
YoY Change
Total Liabilities & Shareholders Equity	$149.2M	$160.5M
YoY Change	-7.06%	27.12%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$20.55M	-$40.23M
YoY Change	-48.92%	113.18%
Depreciation, Depletion And Amortization	$27.00K	$93.00K
YoY Change	-70.97%	16.25%
Cash From Operating Activities	-$12.55M	-$52.21M
YoY Change	-75.96%	213.77%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$42.00K
YoY Change	-100.0%	-130.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$66.02M
YoY Change	-100.0%	737.82%
Cash From Investing Activities	$0.00	$65.98M
YoY Change	-100.0%	752.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$73.13M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$73.50M	$140.0K
YoY Change	52402.14%	600.0%
NET CHANGE
Cash From Operating Activities	-$12.55M	-$52.21M
Cash From Investing Activities	$0.00	$65.98M
Cash From Financing Activities	$73.50M	$140.0K
Net Change In Cash	$60.95M	$13.91M
YoY Change	338.22%	-256.63%
FREE CASH FLOW
Cash From Operating Activities	-$12.55M	-$52.21M
Capital Expenditures	$0.00	$42.00K
Free Cash Flow	-$12.55M	-$52.25M
YoY Change	-75.98%	216.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001566044
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.25
CY2021Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.25
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-38356
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	VYNE THERAPEUTICS INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3757789
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 U.S. Highway 22, Suite 204
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Bridgewater
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
CY2021Q1	dei	City Area Code CityAreaCode	800
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	775-7936
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Trading Symbol TradingSymbol	VYNE
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51386596	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	118516000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57563000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	855000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	855000	USD
CY2021Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1027000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1027000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10755000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15819000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3872000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4591000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	8092000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7404000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	143117000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	87259000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	529000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	555000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1407000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1583000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	4118000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	4345000	USD
CY2021Q1	us-gaap	Assets Assets	149171000	USD
CY2020Q4	us-gaap	Assets Assets	93742000	USD
CY2021Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3490000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4780000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13521000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11452000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3787000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4360000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	647000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	757000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	104000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	104000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	21549000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21453000	USD
CY2021Q1	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	206000	USD
CY2020Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	312000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	784000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	853000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33274000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33174000	USD
CY2021Q1	us-gaap	Other Liabilities OtherLiabilities	457000	USD
CY2020Q4	us-gaap	Other Liabilities OtherLiabilities	457000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	56270000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	56249000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51386596	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51386596	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43205221	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43205221	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	679642000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	603685000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-586746000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-566196000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	92901000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	37493000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	149171000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93742000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4119000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1750000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	601000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	271000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6333000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15953000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16616000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25415000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	22949000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	41368000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19431000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-39889000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1062000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	1067000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-57000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	723000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20550000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40233000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-20550000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-40233000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.42
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	3.79
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48868000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10627000	shares
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-20550000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-40233000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-44000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	1000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-45000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20550000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40278000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17575000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40278000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	303000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1759000	USD
CY2020Q1	vyne	Deemed Dividend To Warrants Holders Due To Warrant Modification DeemedDividendToWarrantsHoldersDueToWarrantModification	0	USD
CY2020Q1	vyne	Share Based Payment Modification Of Terms Incremental Compensation Modification Of Terms Incremental Compensation Cost Reclassified Adjustment ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment	1632000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	91808000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	69535000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	37493000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20550000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	388000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2442000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	92901000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-20550000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-40233000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	93000	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	153000	USD
CY2021Q1	vyne	Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits	-108000	USD
CY2020Q1	vyne	Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits	-13000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2442000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1759000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	66000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	347000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5783000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9297000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-404000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3027000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	205000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	856000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	688000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1849000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12551000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52211000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42000	USD
CY2021Q1	vyne	Proceeds From Business Merger ProceedsFromBusinessMerger	0	USD
CY2020Q1	vyne	Proceeds From Business Merger ProceedsFromBusinessMerger	38641000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	973000	USD
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58456000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	118516000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57601000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	855000	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	855000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119371000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58456000	USD
CY2021Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020Q1	us-gaap	Stock Issued1 StockIssued1	163000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	287000	USD
CY2021Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2020Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	287000	USD
CY2021Q1	vyne	Interest Received InterestReceived	5000	USD
CY2020Q1	vyne	Interest Received InterestReceived	177000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	963000	USD
CY2020Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	117270000	USD
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
CY2020Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	5827000	USD
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2020Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	111443000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	27381000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	65980000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	73127000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	376000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	140000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	73503000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	140000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	60952000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	13909000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-37000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58418000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44584000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119371000	USD
CY2021Q1	vyne	Non Cash Acquisition Of Business Cash Acquired NonCashAcquisitionOfBusinessCashAcquired	0	USD
CY2020Q1	vyne	Non Cash Acquisition Of Business Cash Acquired NonCashAcquisitionOfBusinessCashAcquired	38641000	USD
CY2021Q1	vyne	Non Cash Acquisition Of Business Net Assets After Cash Acquired NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired	0	USD
CY2020Q1	vyne	Non Cash Acquisition Of Business Net Assets After Cash Acquired NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired	72802000	USD
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF OPERATIONS<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc. ("Menlo"), "VYNE" or the "Company") is a specialty pharmaceutical company focused on developing and commercializing proprietary, innovative and differentiated therapies in dermatology and other therapeutic areas. The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as one business segment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Merger</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2019, Menlo, Foamix Pharmaceuticals Ltd. (“Foamix”) and Giants Merger Subsidiary Ltd. (“Merger Sub”), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the “Merger”) on March 9, 2020 (the “Effective Date”).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, the Merger is treated as a “reverse acquisition” under generally accepted accounting principles in the United States (“U.S. GAAP”) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company’s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See “Note 3 – Business Combination” for more information on the Merger.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse stock split and recasting of per-share amounts</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2021, the Company's Board of Directors approved a one-for-four reverse stock split of its outstanding shares of common stock. The reverse stock split was effected on February 12, 2021, at 5:00 p.m. Eastern time. At the effective time, every four issued and outstanding shares of the Company's common stock were converted into one share of common stock. No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each stockholder holding fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company's transfer agent in an amount equal to such stockholder's respective pro rata shares of the total net proceeds from the Company's transfer agent sale of all fractional shares at the then-prevailing prices on the open market. In connection with the reverse stock split, the number of authorized shares of the Company's common stock was also reduced on a one-for-four basis, from 300 million shares to 75 million shares. The par value of each share of common stock remained unchanged. A proportionate adjustment was also made to the maximum number of shares issuable under the Company's 2019 Equity Incentive Plan, 2018 Omnibus Incentive Plan and 2019 Employee Share Purchase Plan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise noted, all common shares and per share amounts contained in the unaudited interim condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products, Product Candidates and Licenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company launched AMZEEQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (minocycline) topical foam, 4% (“AMZEEQ”), a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the U.S. Food and Drug Administration (the "FDA") approved ZILXI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (minocycline) topical foam, 1.5% ("ZILXI"), for the treatment of inflammatory lesions of rosacea in adults. ZILXI became available in pharmacies nationwide in October 2020. AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA for any condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMZEEQ and ZILXI utilize the Company’s proprietary Molecule Stabilizing Technology (MST)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that is also being used in the development of the Company’s product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, the Company announced positive results from a Phase II clinical trial evaluating the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. The Company held an end-of-Phase II meeting with the FDA in the fourth quarter of 2020 and may commence a Phase III program in the next 12 to 18 months based upon the Company's results of operations, which depend on numerous factors, including the COVID-19 pandemic and recent payor formulary decisions. In addition, the Company recently announced a development program for FMX114, which is a </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combination topical gel for the potential treatment of mild-to-moderate atopic dermatitis. The Company plans to conduct a Phase 2a proof-of-concept study for FMX114 in the third quarter of 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company was developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, or NK1-R, given as a once-daily, oral tablet, for the treatment of pruritus, or itch, associated with various conditions including prurigo nodularis, or PN. On April 6, 2020, the Company announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN, studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. The Company does not currently intend to further pursue the development of serlopitant. As a result, in the second quarter of 2020, the Company recorded a full impairment charge related to the IPR&D and Goodwill assets in its unaudited condensed consolidated statement of operations and comprehensive loss. See "Note 3 - Business Combination" for more information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively pursuing opportunities to out-license its products and product candidates to third parties for development and commercialization outside the United States and entered into a license agreement with Cutia Therapeutics (HK) Limited (“Cutia”) in April 2020. See "Note 4 - Revenue Recognition." The Company has also licensed certain technology under development and licensing agreements to various pharmaceutical companies for development of certain products combining the Company’s foam technology with the licensee’s proprietary drugs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched AMZEEQ in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company’s activities prior to the commercial launch of AMZEEQ had primarily consisted of developing product candidates, raising capital and performing research and development activities. Since inception, the Company has incurred losses and negative cash flows from operations. For the three months ended March 31, 2021, the Company incurred a net loss of $20.6 million and used $12.6 million of cash in operations. As of March 31, 2021, the Company had cash, cash equivalents, restricted cash and investments of $120.4 million and an accumulated deficit of $586.7 million. The Company's outstanding debt at March 31, 2021 was $35.0 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company does not successfully commercialize AMZEEQ, ZILXI or any of its future product candidates, it may be unable to achieve profitability. Accordingly, the Company may be required to obtain further funding through public or private debt or equity offerings, or other arrangements. Adequate additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on acceptable terms, it may be forced to delay, reduce or eliminate its research and development programs or commercialization and manufacturing efforts. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of recent unfavorable payor formulary decisions, coupled with continued uncertainties surrounding the impact of COVID-19, the Company’s current projections indicate that it may not be in compliance with certain revenue covenants in each of the subsequent periods of 2021. The Company believes that its existing cash, cash equivalents and investments as of March 31, 2021 and projected cash flows from revenues will provide sufficient resources to fund its current ongoing needs, including all potential debt obligations, for at least the next twelve months from the issuance of these financial statements. Additionally, the Company is monitoring its results of operations in light of recent unfavorable payor formulary decisions and the continued impact of the COVID-19 pandemic. However, the amounts and timing of the Company's actual expenditures may vary significantly depending on numerous factors, including the impact of COVID-19 pandemic, the Company's ability to successfully commercialize AMZEEQ and ZILXI, the Company’s ability to satisfy the minimum net revenue covenants in the Amended and Restated Credit Agreement (See “Note 8 - Long-Term Debt” for additional information), and any unforeseen cash needs. In addition, the Company may seek to restructure its current debt arrangements, obtain additional financing and reduce discretionary spending in order to achieve its longer-term strategic plans. There is no assurance the Company will be successful in restructuring its debt arrangements, obtaining additional financing on acceptable terms or in implementing these other other actions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a significant impact on the Company's operations. Access to healthcare providers has been limited, which has dampened sales and negatively impacted the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. On August 5, 2020, the Company and its lenders amended the minimum net revenue covenant in the Amended and Restated Credit Agreement following an assessment of the impact of the pandemic on the Company's revenue. See "Note 8 - Long-Term Debt." Access to healthcare providers has remained limited through the first quarter of 2021. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition and liquidity will depend on future developments that are highly uncertain, subject to change and will continue to evolve with geographical re-openings, surges in cases and the vaccination effort. If the activities of the Company's sales force continue to be disrupted or patients elect not to visit their healthcare providers during the pandemic, the Company may continue to generate less revenue </span></div>than expected, which could have a material adverse effect on its financial results and liquidity as well as hinder its ability to satisfy certain covenants contained in the Amended and Restated Credit Agreement.
CY2021Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-20600000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12600000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	120400000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-586700000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	35000000.0	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company’s estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a significant impact on the Company's operations. Access to healthcare providers has been limited, which has dampened sales and negatively impacted the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. Access to healthcare providers has remained limited through the first quarter of 2021. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition and liquidity will depend on future developments that are highly uncertain, subject to change and will continue to evolve with geographical re-openings, surges in cases and the vaccination effort. If the activities of the Company's sales force continue to be disrupted or patients elect not to visit their healthcare providers during the pandemic, the Company may continue to generate less revenue than expected, which would have a material adverse effect on its financial results and liquidity as well as hinder its ability to satisfy certain covenants contained in the Amended and Restated Credit Agreement. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition. In 2020, the Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information). The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.</span></div>
CY2021Q1	us-gaap	Derivative Number Of Instruments Held DerivativeNumberOfInstrumentsHeld	0	derivativeInstruments
CY2020Q1	us-gaap	Derivative Number Of Instruments Held DerivativeNumberOfInstrumentsHeld	0	derivativeInstruments
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Business Combination Effective Exchange Ratio BusinessCombinationEffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2021Q1	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	18636103	shares
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders PostMergerParentOwnershipByPreMergerSubsidiaryShareholders	0.82
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Parent Stockholders PostMergerParentOwnershipByPreMergerParentStockholders	0.18
CY2020Q1	vyne	Business Combination Acquiree Common Stock Rights Converted To Common Stock BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock	19600000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4500000	USD
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2021Q1	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	18636103	shares
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders PostMergerParentOwnershipByPreMergerSubsidiaryShareholders	0.82
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Parent Stockholders PostMergerParentOwnershipByPreMergerParentStockholders	0.18
CY2020Q2	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84700000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	104400000	USD
CY2020Q2	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2021Q1	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	18636103	shares
CY2020Q2	us-gaap	Share Price SharePrice	1.40
CY2020Q1	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	0	USD
CY2020Q1	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	12043000	USD
CY2020Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1750000	USD
CY2020Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-37641000	USD
CY2020Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-0.62
CY2020Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.62
CY2020Q1	vyne	Adjustments To Supplemental Proforma Transaction Costs AdjustmentsToSupplementalProformaTransactionCosts	14931000	USD
CY2020Q1	vyne	Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation	7199000	USD
CY2020Q1	vyne	Adjustments To Supplemental Proforma Combined Results Of Operations AdjustmentsToSupplementalProformaCombinedResultsOfOperations	22130000	USD
CY2021Q1	vyne	Revenue Recognition Distribution Trade Discounts And Allowances RevenueRecognitionDistributionTradeDiscountsAndAllowances	15600000	USD
CY2020Q1	vyne	Revenue Recognition Distribution Trade Discounts And Allowances RevenueRecognitionDistributionTradeDiscountsAndAllowances	8200000	USD
CY2021Q1	vyne	Estimate Of Product Return Rate Minimum EstimateOfProductReturnRateMinimum	0.02
CY2021Q1	vyne	Estimate Of Product Return Rate Maximum EstimateOfProductReturnRateMaximum	0.03
CY2021Q1	us-gaap	Marketable Securities MarketableSecurities	1027000	USD
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	1027000	USD
CY2021Q1	vyne	Derivate Costs For Year DerivateCostsForYear	0	USD
CY2021Q1	vyne	Derivative Maximum Term Of Contract DerivativeMaximumTermOfContract	P1Y
CY2020Q4	us-gaap	Derivative Amount Of Hedged Item DerivativeAmountOfHedgedItem	0	USD
CY2021Q1	us-gaap	Derivative Amount Of Hedged Item DerivativeAmountOfHedgedItem	0	USD
CY2021Q1	vyne	Foreign Exchange Risk Lien On Checking Account For Bank Guarantees Granted For Hedging Transactions ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions	300000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2021Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	15300000	USD
CY2020Q4	us-gaap	Restricted Investments RestrictedInvestments	0	USD
CY2021Q1	us-gaap	Restricted Investments RestrictedInvestments	0	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2021Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3746000	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	4042000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1002000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	662000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3344000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2700000	USD
CY2021Q1	us-gaap	Inventory Gross InventoryGross	8092000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	7404000	USD
CY2019Q3	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1100000	USD
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1000000.0	USD
CY2020Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1000000.0	USD
CY2020Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	100000	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	100000	USD
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	50000000.0	USD
CY2021Q1	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	18636103	shares
CY2021Q1	vyne	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue	7500000	USD
CY2020Q1	vyne	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue	4300000	USD
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2442000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1759000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	686000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	761000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	151000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1598000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	167000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1431000	USD
CY2021Q1	vyne	Restricted Investments To Secure Lease Agreements RestrictedInvestmentsToSecureLeaseAgreements	600000	USD

Files In Submission

Name	View Source	Status
0001566044-21-000025-index-headers.html	Edgar Link	pending
0001566044-21-000025-index.html	Edgar Link	pending
0001566044-21-000025.txt	Edgar Link	pending
0001566044-21-000025-xbrl.zip	Edgar Link	pending
exhibit101saik-vyneemploym.htm	Edgar Link	pending
exhibit102harsch-vyneemplo.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vyne-20210331.htm	Edgar Link	pending
vyne-20210331.xsd	Edgar Link	pending
vyne-20210331xexx311.htm	Edgar Link	pending
vyne-20210331xexx312.htm	Edgar Link	pending
vyne-20210331xexx321.htm	Edgar Link	pending
vyne-20210331xexx322.htm	Edgar Link	pending
vyne-20210331_cal.xml	Edgar Link	unprocessable
vyne-20210331_def.xml	Edgar Link	unprocessable
vyne-20210331_htm.xml	Edgar Link	completed
vyne-20210331_lab.xml	Edgar Link	unprocessable
vyne-20210331_pre.xml	Edgar Link	unprocessable
vyne1a.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VYNE
VYNE Therapeutics Inc. Stock $vyne

2021 Q1 Form 10-Q Financial Statement

#000156604421000025 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE VYNE Therapeutics Inc. Stock $vyne

2021 Q1 Form 10-Q Financial Statement

#000156604421000025 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE
VYNE Therapeutics Inc. Stock $vyne